Summary
To evaluate the response rate and toxicity of the combination of irinotecan (CPT-11) and cisplatin in a neoadjuvant setting, a phase II study was conducted regarding the regimen of this combination in patients with locally advanced cervical cancer. Eligibility included patients with previously untreated stage Ib2, IIb, or IIIb squamous cell carcinoma with good performance status. CPT-11 (60 mg m–2) was administered intravenously on days 1, 8 and 15, followed by cisplatin (60 mg m–2) given intravenously on day 1. Treatment was repeated every 4 weeks for a total of two or three cycles. Among 23 eligible patients (median age: 59 years), three showed complete response (13%), 15 showed partial response (65%), for an overall response rate of 78% (95% confidence interval 58–90%). Stable disease was observed in four cases (17%) and progressive disease in one (4%). The median time to failure and median survival time have not yet been reached. Of the 52 treatment cycles administered, diarrhoea and grade 3 or 4 neutropenia were observed in 10% and 75% respectively. There were no therapy-related deaths. The combination of CPT-11 with cisplatin is a promising regimen for neoadjuvant chemotherapy in locally advanced cervical cancer. The toxicities of this regimen are well tolerated.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Alberts, DS, Kronmal, R & Baker, LH (1987). Phase II randomized trial of cisplatin chemotherapy of recurrent or metastatic squamous cell carcinoma of the cervix: a Southwest Oncology Group Study. J Clin Oncol 5: 1791–1795.
Benedetti-Panici, P, Greggi, S & Scambia, G et al (1991). High-dose cisplatin and bleomycin neoadjuvant chemotherapy plus radical surgery in locally advanced cervical carcinoma: a preliminary report. Gynecol Oncol 41: 212–216.
Hsiang, YH, Liu, LF & Wall, ME et al (1989). DNA topoisomerase I mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res 49: 4835–4839.
Irvin, WP, Price, FV & Bailey, H et al (1998). A phase II study of irinotecan (CPT-11) on patients with advanced squamous cell carcinoma of the cervix. Cancer 82: 328–333.
Kano, Y, Suzuki, K & Akutsu, M et al (1992). Effects of CPT-11 in combination with other anticancer agents in culture. Int J Cancer 50: 604–610.
Kunimoto, T, Nitta, K & Tanaka, T et al (1987). Antitumor activity of 7-ethyl-10-[4- (1-piperidino)-10-piperidino]carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 47: 5944–5947.
Lahousen, M, Pickel, H & Tamussino, K (1987). Chemotherapy for advanced and/or recurrent cervical cancer. Arch Gynecol 240: 247–252.
Matsuzaki, T, Yokokura, T & Mutai, M et al (1988). Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice. Cancer Chemother Pharmacol 21: 308–312.
Minagawa, Y, Kigawa, J & Ishikawa, H et al (1994). Synergistic enhancement of cisplatin cytotoxicity by SN-38, an active metabolite of CPT-11, for cisplatin-resistant HeLa cells. Jpn J Cancer Res 85: 966–971.
Oken, MM, Creech, RH & Tormey, DC et al (1982). Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649–655.
Omura, GA (1992). Current status of chemotherapy for cancer of the cervix. Oncology 6: 27–32.
Parkin, DM, Laara, E & Muir, CS (1988). Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 41: 184–197.
Scarabelli, C, Zarrelli, A, Gallo, A & Visentin, MC (1995). Multimodal treatment with neoadjuvant intraarterial chemotherapy and radical surgery in patients with stage IIIb–IVa cervical cancer. A preliminary study. Cancer 76: 1019–1026.
Souhami, L, Gil, RA & Allan, SE et al (1991). A randomized trial of chemotherapy followed by pelvic radiation therapy in stage IIIB carcinoma of the cervix. J Clin Oncol 9: 970–977.
Sugiyama, T, Takeuchi, S & Noda, K et al (1995). Phase I study of irinotecan (CPT-11) in combination with cisplatin in cervical cancer. Proc Am Soc Clin Oncol 13: A1546
Sugiyama, T, Nishida, T, Hasuo, Y, Fujiyoshi, K & Yakushiji, M et al (1998a). Neoadjuvant intraarterial chemotherapy followed by radical hysterectomy and/or radiotherapy for locally advanced cervical cancer. Gynecol Oncol 69: 130–136.
Sugiyama, T, Noda, K & Yakushiji, M (1998b). Phase II study of irinotecan (CPT-11) in combination with cisplatin in cervical cancer. Proc Am Soc Clin Oncol 17: 1360
Sundfor, K, Trope, CG & Hogberg, T et al (1996). Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma. A randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A. Cancer 77: 2371–2378.
Takeuchi, S, Dobashi, K & Fujimoto, S et al (1991). A late phase II study of CPT-11 on uterine cervical cancer and ovarian cancer. Gan To Kagaku Ryoho 18: 1681–1698.
Thigpen, T, Shingleton, H, Homesley, H, Lagasse, L & Blessing, J (1981). Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. Cancer 48: 899–903.
Thigpen, T, Vance, R, Puneky, L & Khansur, T (1995). Chemotherapy as a palliative treatment in carcinoma of the uterine cervix. Semin Oncol 22: 16–24.
Tsuruo, T, Matsuzaki, T & Matsushita, M et al (1988). Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumor in vitro and vivo. Cancer Chemother Pharmacol 21: 71–74.
Vermorken, JB (1993). The role of chemotherapy in squamous cell carcinoma of the uterine cervix: a review. Int J Gynecol Cancer 3: 129–142.
Verschraegen, CF, Levy, T & Kudelka, AP et al (1997). Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. J Clin Oncol 15: 625–631.
Wall, ME, Wani, MC & Cook, CE et al (1996). Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from. Camptotheca acuminata. J Am Chem Soc 88: 3888–3890.
WHO Handbook for Reporting Results of Cancer Treatment (1979). WHO Offset Publication No. 48. World Health Organization: Geneva
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Sugiyama, T., Nishida, T., Kumagai, S. et al. Combination therapy with irinotecan and cisplatin as neoadjuvant chemotherapy in locally advanced cervical cancer. Br J Cancer 81, 95–98 (1999). https://doi.org/10.1038/sj.bjc.6690656
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690656
Keywords
This article is cited by
-
Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics
Clinical Pharmacokinetics (2018)
-
Prognostic risk model development and prospective validation among patients with cervical cancer stage IB2 to IIB submitted to neoadjuvant chemotherapy
Scientific Reports (2016)
-
Phase II clinical study of neoadjuvant chemotherapy with CDDP/CPT-11 regimen in combination with radical hysterectomy for cervical cancer with a bulky mass
International Journal of Clinical Oncology (2016)
-
Prognostic value of pathological response to neoadjuvant chemotherapy in bulky stage Ib2 and IIa cervical squamous cell cancer patients
Virchows Archiv (2016)
-
Analysis of prognostic factors for patients with bulky squamous cell carcinoma of the uterine cervix who underwent neoadjuvant chemotherapy followed by radical hysterectomy
International Journal of Clinical Oncology (2015)